Berkshire said operating profit fell 32% to $5.48 billion from $8.07 billion a year earlier. Net income rose 82% to $30.14 billion, or $18,994 per Class A share, from $16.52 billion, or $10,119 per share, a year earlier. Berkshire’s share price is lagging the Standard & Poor’s 500 for a second straight year despite outperforming from July to September. …read more […]
(Bloomberg) — Warren Buffett is keeping up his record pace of buybacks.Berkshire Hathaway Inc. spent the third quarter buying back $9 billion of its own stock, after Buffett abandoned his long-held aversion to that use of capital. That total was more than the conglomerate has repurchased in any full year.Key InsightsBuffett was able to chip away at Berkshire’s cash pile in the third quarter, with that war chest dropping slightly to $145.7 billion. The funds, which still give him plenty of capital to deploy into acquisitions, stock purchases or buybacks, have recently been accumulating faster than Buffett can put it …read more […]
Kohl’s temporarily closed its nearly 1,200 stores nationwide in the seven weeks of the coronavirus outbreak, causing sales to plunge 33% in the first half of the fiscal year. …read more […]
Aquestive Therapeutics, Inc. (NASDAQ:AQST) missed earnings with its latest quarterly results, disappointing… …read more […]
Appian Corporation (NASDAQ:APPN) just released its latest quarterly results and things are looking bullish. Revenues… …read more […]
As you might know, Apache Corporation (NASDAQ:APA) just kicked off its latest quarterly results with some very strong… …read more […]
ADMA Biologics, Inc. (NASDAQ:ADMA) just released its latest third-quarter results and things are looking bullish. ADMA… …read more […]
Barrick Gold Corporation (TSE:ABX) just released its third-quarter report and things are looking bullish. The company… …read more […]
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) just released its latest third-quarter report and things are not looking… …read more […]
The FDA still could decide to approve the drug, aducanumab, making it the first new Alzheimer’s treatment in decades. Several of the 11 panel members expressed resentment that the FDA’s early view of aducanumab – which was made public on Wednesday – was biased toward a favorable outcome for Biogen. …read more […]
(Bloomberg) — With Joe Biden on a path to winning the U.S. presidency but control of the Senate still up in the air, investors in European stocks have been forced to review their outlook for some key industries.Market players had spent months positioning for post-election outperformance in European renewable-energy and cyclical stocks, accompanied by weakness in health care and technology. The thinking was that a “blue wave” of Democratic wins would lead to increased fiscal stimulus and support for alternative power, along with higher corporate taxes and possibly legislation that hurt drug companies.Now, Biden looks to be just squeaking out …read more […]
The current rally is being driven by momentum. If this continues then look for the move to extend into the main 50% level at $1970.10. …read more […]
Chief among their concerns: that small-caps will bear the brunt of aggressive measures Biden could adopt to combat the pandemic, without benefiting from a large stimulus bill if Senate Republicans block his efforts there. Democrats could still take over the Senate if Georgia’s two contested seats go to a January runoff as is now expected. …read more […]
2020 has provided a reversal of fortune for MannKind (MNKD). After several difficult years, the diabetes focused biotech’s stock has been on the mend and is up by 77% year-to-date.However, according to BTIG analyst Robert Hazlett, there’s plenty of upside yet to come. The 5-star analyst has a Buy rating on MNKD shares along with a $4 price target. Investors could be pocketing gains of a hefty 75%, should Hazlett’s thesis play out over the coming months. (To watch Hazlett’s track record, click here)Hazlett’s confidence in MannKind is based on 2 main drivers; The first is the increasing sales of …read more […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
